Eli Lilly's President of Bio-Medicines on Dermira Acquisition

Publish date:
Video Duration:

Friday morning, Eli Lilly (LLY) - Get Report announced that it was acquiring Dermira (DERM) - Get Report

The price is 2.2% higher than Dermira's closing price Thursday of $18.34. The shares have jumped more than 234% over the past three months.

In a statement, Eli Lilly said the acquisition of Dermira would expand its immunology pipeline with the addition of dermatitis treatment lebrikizumab, which is being evaluated in a Phase 3 clinical development program in adolescent and adult patients.

Patrik Jonsson, president of Bio-Medicines at Eli Lilly, joined TheStreet to break down why now was the time to buy Dermira. 

"Well, we believe that Dermira is a very nice fit into our commitment to immunology and particularly dermatology. Dermira is a company that is specialized and dedicated to chronic skin conditions and we, at Eli Lilly, have now been present in the area of immunology for quite a few years," said Jonsson. 

Watch the full video above for more on the acquisition.

Online real estate platform CrowdStreet delivers investors a new way to diversify their portfolios with real estate. Individual investors can use CrowdStreet’s leading online marketplace to connect with a wide array of commercial real estate opportunities and projects to make investing in real estate easy! Download the Real Estate Guide.

Catch up on the Latest News, Features & Webinars on TheStreet!